Subject Index to Volume 16

N-Acetylglutamine, infusion, effect on plasma amino acid concentrations, TPN-fed enterectomized dog, 117
Acquired immunodeficiency syndrome
  complications of long-term venous access, 455
  lipid-based parenteral nutrition, clinical and immunologic effects, 165, 496 (letters)
Alanyl-glutamine, intestinal mucosal atrophy prevented by, TPN-fed rat, 110
Albumin, concurrent with TPN, sick neonates, 49
Aluminum
  content standards, parenteral nutrition solutions (letters), 92
  plasma and urinary levels, term and preterm infants, 157
American Society for Parenteral and Enteral Nutrition, presidential address, 301
Amino acids
  addition, liquid diet, enteral *vs* parenteral route, rat, 259
  branched chain, metabolic effect, septic rat, 236
  intravenous, increased energy expenditure after, rat, 142
  metabolism, chemotherapy-treated colon cancer patients, 65S
  pediatric formulation, total nutrition admixture with, 64
  plasma concentrations, glutamine infusion effect, TPN-fed enterectomized dog, 117
  skeletal muscle, response to thermal injury and infection, current summary, 183
  transport
    carrier-mediated, regulation of, 569
    transmembrane, protein kinetics and, dog muscle, 305
Ammonia, colonic fermentation of dietary fibers to, 433
Anorexia
  as outcome variable of nutrition in advanced cancer, 88S
  early cancer, changes in plasma free tryptophan and feeding indexes, rat, 56S
Antioxidant, parenteral glutathione monoester effect on, rat tissue, 413
Apolipoproteins, serum levels, oat bran cereal effect, hyperlipoproteinemic patients, 533
Arginine
  in vivo action on T lymphocytes, athymic nude mice, 429
  parenteral infusion, as sole nitrogen source, 423
Aspiration
  nasoenteric feeding tube-related, postpyloric *vs* intragastric placement, 59
  pulmonary, risk, enteral nutrition support patients, 160

Bacteria
  antibiotic-resistant, enteral feeding tubes contaminated by, 552
  contamination by, enteral diet delivery systems, 369
  translocation, essential fatty acids and, mouse intestine, 122
Bioelectrical impedance, body position and splint effect, 408
Body composition, research, clinical nutrition implications, 197
Body fat, measurement of, intermethod comparisons, current summary, 181
Body position
  effect, measurement of bioelectrical impedance, 408
  risk factor for gastroesophageal reflux, intubated patients receiving enteral nutrition, 419
Body weight, changes, after acute spinal-cord injury, 11
Bone disease, related to parenteral nutrition, overview, 386, 400 (letter)
Bone marrow
  transplant
    glutamine-supplemented parenteral nutrition after, current summary, 589
    TPN formula comparison (letter), 192
Book reviews, 88, 186, 293, 491, 592
Bronchoscope, fiberoptic, duodenal feeding tube placement with, 579

Calcium, excretion, acute spinal-cord injury patients, 11
Calorie
  requirements, calculation, variability of Harris-Benedict equation, 566
  restriction, role in *Salmonella* outcome, mice, 561
Calorimetry, circulatory indirect, resting energy expenditure estimated with (letter), 497
Cancer
  advanced
    anorexia as outcome variable of nutrition in, 88S
    home parenteral nutrition in patients with (letter), 190
  cachexia
    cytokine role, 43S
    hormonal and metabolic abnormalities, 60S
  clinical nutrition trial, health outcome benefits, 106S
  home parenteral nutrition in patients with, 93S
  malnutrition, supplement preface, iv
  metabolic response, effect of tumor bulk, current summary, 586
  nutrition support, clincal outcome studies, optimal design for, 112S
  perioperative nutrition in patients with, 100S
  stimulation of tumor growth by nutrition support, 72S, 76S
Carbohydrate, postprandial glycemic response and, type I diabetes, 69
Catheter
  central venous
    complications in AIDS patients receiving home parenteral nutrition, 455
    cuffed polyurethane, evaluation, pediatric surgical patients, 384
    duplex Doppler ultrasound role, 264
    silastic, redirection techique for malposition, pediatric patients, 473
    thrombotic occlusion, urokinase infusion effect, 129
  dislodgement, forceful coughing, correction (letters), 298
  fragment, breakage, complication of nonsurgical transvenous retrieval, 175
  hub contamination, new connection device effect, 178
  inadvertent arterial placement, generalized seizures following, 284
  new connection device, for prevention of sepsis during TPN, 581
  -related vascular erosions, risk factors for (letter), 595
  thrombosis, urokinase infusion for (letters), 596
  totally implantable subcutaneous infusion port, spontaneous partial fracture, 75
  triple-lumen subclavian, safety evaluation, TPN administration, 403
Cell, proliferation, measurement, cancer patients, 76S
Cell membrane, amino acid transport across, mechanisms, models, menus, and mediators, 569
Cellulose, effect on fat absorption, after small bowel resection, rat, 255
Chemotherapy
  influence of enteral glutamine on, rat, 83S
  metabolic response, colon cancer patients, 65S
Cholecystokinin, secretion, intravenous fat effect, 16
Cholesterol, serum levels, oat bran cereal effect, hyperlipoproteinemic patients, 533
Cirrhosis, clearance of medium-chain triglycerides, 279
Clintec Nutrition Company, correction of misrepresentation (letters), 194
Colon
  cancer, metabolic response to chemotherapy, 65S
  mucosa, short-chain fatty acid effect, *in vitro* study, 43
  structure and function, short-chain fatty acid effect, rat, 1
Contamination, bacterial: *see* Bacteria
Copper, concentrations, prefilter and postfilter, pediatric parenteral nutrition solutions, 460
Creatinine, excretion, acute spinal-cord injury patients, 11
Crohn's disease
  active, enteral nutrition versus drug treatment, current summary, 84
  intermittent administration of defined formula diet, growth failure improved by, children, 499
Cysteine/cystine, concentrations, prefilter and postfilter, pediatric parenteral nutrition solutions, 460
Cytokine
  role in pathogenesis of cancer cachexia, 43S
  role in pathophysiology of cancer cachexia, 50S

Defined formula diet, intermittent administration, effect on growth failure, pediatric Crohn's disease, 499
Denutrition, ornithine α-ketoglutarate vs. glutamine supplementation during, food-deprived, rat, 505
Diabetes, postprandial blood glucose response, comparison, enteral feeding products, 69
Diarrhea
  defining and reporting in tube-fed patients, current summary, 488
  related to tube feeding (letter), 192
Dicarboxylic salt, even-numbered carbon atom, as fuel substrate, TPN, 32
Dietary fiber, colonic fermentation, short-chain fatty acids and ammonia produced by, 433
Differentiation factor, role in cancer cachexia, 50S

Echocardiography, role, endocarditis complicating TPN, 168
Endocarditis, complication of TPN, case reports, 168
Endotoxin, combined with protein malnutrition, systemic and intestinal immunity impaired by, mice, 25
Energy expenditure
  estimation (letter), 595
  intravenous amino acid effect, rat, 142
  postprandial, after meal ingestion, cirrhotic patients, 445
  resting
    acute spinal-cord injury patients, 11
    estimate by circulatory indirect calorimetry (letter), 497
    measurement, chronic obstructive lung disease, 364
    measurement of (letter), 193
    normalization, in liver disease (letter), 400
    operative stress effect, neonate, 333
Enteral diet/formula
  delivery system, retrograde bacterial contamination of, 369
  dietary fat composition effect, experimental peritonitis, current summary, 87
  fiber-containing (letters), 91
  fiber supplementation, gastrointestinal effects, 538
  high-calorie, high protein, metabolic and infectious sequelae, Guillain-Barré syndrome, 464
  peptide *vs* standard formula, tolerance and outcome, 20
  product comparison, glucose response in type I diabetics, 69
  supply rate, gut mass and, rat, 39
Enteral nutrition
  alcoholic liver disease improved by, current summary, 289
  comparison, drug treatment, active Crohn's disease, current summary, 84
  feeding tube-related aspiration, postpyloric *vs* intragastric placement, 59
  gastroesophageal reflux associated with, body position effect, 419
  microbial contamination of nasogastric tubes, 552
  phenytoin interaction with (letters), 95
  standardized order forms, prospective study, 149
  support, clinical assessment tool in traumatized patients, current summary, 85
  tolerance, elemental *vs* polymeric feedings, current summary, 587
  total, intolerance, residual volume as marker for, 99

Fat
  absorption, pectin and cellulose effects, after small bowel resection, rat, 255
  effect on liver regeneration, comparison, glucose, after partial hepatectomy, rat, 152
  elimination, acute renal failure, current summary, 590
  intravenous
    cholecystokinin and gallbladder responses, 16
    short-term infusion, effect on serum lipids (letter), 295
Fat emulsion, containing medium-chain triglycerides, metabolic clearance, cirrhotic patients, 279
Fatty acids
  essential, role, translocation of intestinal bacteria, mouse, 122
  increased oxidation, malnourished cancer patients, 60S
  long-chain polyunsaturated, effect of postnatal age and dietary nucleotides, weanling rat, 322
  polyunsaturated, plasma levels, liver cirrhosis, 359
  short-chain
    colonic fermentation of dietary fibers to, 433
    effect on colonic function and structure, rat, 1
    effect on human colonic mucosa *in vitro*, 43
Fatty liver, sepsis-induced, prevention by fish oil diet, rat, 353
Feeding tube
  defining and reporting diarrhea in patients with, current summary, 488
  duodenal, placement with fiberoptic bronchoscope, 579
  formula
    diarrhea related to (letter), 192
    fiber-containing (letters), 91
    fiber-enriched, benefits (letters), 297
  nasoenteric, postpyloric *vs* intragastric placement, 59
  nasogastric
    continuous *vs* intermittent, elderly patients, 525
    microbial contamination, 552
    risk factor for gastroesophageal reflux, 419
Fiber
  colonic crypt proliferation, mediation, short-chain fatty acid, 43
  postprandial glycemic response and, type I diabetes, 69
Fiber supplementation, modified guar gum *vs* soy polysaccharide, enteral formula diet, 538
Fish oil, fatty liver prevented by, septic rat, 353
Folate, requirement, low birth weight infants during TPN, 241

Gallbladder, motility, intravenous fat effect, 16
Gastroesophageal reflux, body position effect, intubated patients receiving enteral nutrition, 419
Gastrointestinal fistula, somatostatin effect, current summary, 290
Gastroma, duodenal feeding tube via, placement with fiberoptic bronchoscope, 579
Gastrostomy tube, conversion from continuous to intermittent feedings (letter), 494
Geriatrics, nasogastric tube feeding, continuous *vs* intermittent, 525
Glucose
  effect on liver regeneration, comparison, fat, after partial hepatectomy, rat, 152
  increased production, malnourished cancer patients, 60S
  metabolism
    chemotherapy-treated colon cancer patients, 65S
    during glucose and insulin infusion, underweight patients, 5
    excess xylitol effect, TPN-fed rat, 521
  oxidation, medium-chain triglyceride effect, during TPN, dog, 451
Glutamine
  comparison with ornithine α-ketoglutarate, refeeding of food-deprived rats, 505
  intravenous
    effect on gut morphology after radiation injury, rat, 440
    effect on plasma amino acid concentrations, TPN-fed enterectomized dog, 117
  supplementation, effect on chemotherapy, 83S
Glutathione, parenteral monoester, effect on tissue antioxidant stores, rat, 413
Glutathione peroxidase, platelet activity, as index of selenium status, long-term TPN, 54
Glycylglutamine, metabolism, postabsorptive and starved subjects, current summary, 489
Growth failure, effect of intermittent defined formula diet, children with Crohn's disease, 499
Guar gum, modified, fiber supplementation by, enteral formula diet, 538
Guillain-Barré syndrome, evaluation of enteral nutrition support, 464
Gut mass, enteral nutrient supply rate and, rat, 39

Harris-Benedict equation, variability of, recently published textbooks, 566
Hemodifiltration, continuous, renal failure patient, 379
Heparin solution, vancomycin stability in, catheter-related infection, 268
High-pressure liquid chromatography, vitamin E measurement, pediatric patients receiving intravenous lipid emulsions, 133
Hypercatabolism, enteral nutrition support for, Guillain-Barré syndrome, 464
Hyperlipoproteinemia type IIa, single oat bran cereal breakfast effect, 533
Hypermetabolism, enteral nutrition support for, Guillain-Barré syndrome, 464

Hypoalbuminemia
enteral nutrition, peptide *vs* standard formula, 20
neonatal, albumin administration with TPN, 49
Hypogonadism, malnourished cancer patient, effects on host-tumor interaction, 60S
Hypoxia, anaerobic muscle function after malnutrition, rat, 219

Ileum, hydrolase activity, effect of amino acid addition to liquid diet, rat, 259
Immunity
parenteral arginine infusion effect, postoperative patients, 423
protein and zinc malnutrition effect, mouse, 232
systemic and gut-associated, protein malnutrition effect, 25
Infant: *see* Pediatrics
Infection
catheter-related, vancomycin stability in heparin and TPN solutions, 268
murine response, protein and zinc underfeeding effect, 232
Injury: *see also* Trauma
enteral nutrient delivery rate after, gut mass and, rat, 39
spinal cord, nutritional and metabolic response, 11
thermal, skeletal muscle amino acid response, current summary, 183
Insulin
infusion, glucose metabolism during, severely underweight patients, 5
resistance, malnourished cancer patients, 60S
Intensive care unit, composition of phospholipid fatty acids, red cell membranes, diet comparison, 136
Interferon-γ, role in cancer cachexia, 43S, 50S
Interleukin-1, role in cancer cachexia, 43S, 50S
Interleukin-6, role in cancer cachexia, 50S
Intestine
bacterial translocation, essential fatty acids and, mouse, 122
chronic obstruction, 3-year analysis, home parenteral nutrition, 327
mucosal atrophy, prevention, alanyl-glutamine, TPN-fed rat, 110

Jejunostomy
feeding, postoperative nutritional support, current summary, 395
subcutaneous, procedure for, 286
Jejunum
hydrolase activity, effect of amino acid addition to liquid diet, rat, 259
mucosal injury, role of hydrolytic products of food digestion, current summary, 396

Kidney failure: *see* Renal failure

Letters to the editor, 91, 189, 295, 399, 494, 594
Lecithin, hepatic steatosis decreased by, long-term TPN patients, current summary, 487
Lipid
addition to TPN, hepatic steatosis prevented by, rat, 106
-based parenteral nutrition, clinical and immunologic effects, AIDS, 165, 496 (letters)
effect on liver fatty acids and prostaglandin synthesis, mouse peritoneal cells, 316
glycerol and amino acids combined with, peripheral parenteral nutrition, 374
emulsion
hepatic cytolytic and cholestatic changes related to changes in, 78
intravenous, vitamin E measurement, pediatric patients, 133
serum levels, short-term infusion of intravenous fat (letter), 295
short-term manipulation, effect on outcome, murine sepsis, 343
Lipid source, effect of tumor growth, comparison of three TPN solutions, rat, 545
Lipolysis, increased, malnourished cancer patients, 60S
Lipopolysaccharide, deleterious effects, protection by polymyxin B, rat, 529
Lipoproteins, serum levels, oat bran cereal effect, hyperlipoproteinemic patients, 533
Liquid diet
amino acids addition, enteral vs parenteral route, rat, 259
long-term, weight-losing cancer patients, 275
Liver
chronic encephalopathy, fatty acid levels in cirrhotic patients with, 359
cirrhosis: *see* Liver cirrhosis
cytolytic and cholestatic changes, after lipid emulsion changes, short bowel disease, 78
disease
alcoholic, enteral nutrition effect, current summary, 289
resting energy expenditure, normalization (letter), 400
fatty acids, dietary triglyceride effect, mouse peritoneal cells, 316
long-term parenteral nutrition effect (letters), 494
regeneration, glucose *vs* fat, after partial hepatectomy, rat, 152
steatosis
lecithin effect, long-term TPN patients, current summary, 487
pathogenesis, TPN-fed rat (letters), 399
prevention, lipid addition to TPN, rat, 106
TPN-associated, polymyxin B effect, 529
Liver cirrhosis
plasma polyunsaturated fatty acids, chronic hepatic encephalopathy patients, 359
postprandial energy expenditure in patients with, meal ingestion effect, 445
Liver test, abnormalities, TPN patients, 348
Lung disease: *see* Pulmonary disease
Lymphocyte, mitogenesis, parenteral arginine evaluation, 423

Macronutrient, before and after meal ingestion, cirrhotic patients, 445
Malnutrition
effect on *Salmonella* outcome, mice, 561
hypoalbuminemic, subtype of protein-calorie malnutrition, 337
marasmic, subtype of protein-calorie malnutrition, 337
muscle performance and, anaerobic conditions, rat, 219
protein, systemic and gut-associated immunity impaired by, 25
protein-calorie, differentiation of subtypes, 337
protein energy, defects in body composition, 197
Metabolic expenditure: *see* Energy expenditure
Metabolic rate, after acute spinal-cord injury, 11
Metabolism, molecular cell biology role, 477
Methotrexate, enteral glutamine supplementation effect, rat sarcoma, 83S
3-Methylhistidine, excretion, acute spinal-cord injury patients, 11
Molecular cell biology, experimental and clinical applications, nutrition and metabolism, 477
Muscle
fast- and slow-twitch, malnutrition effect, rat, 219
glutamine concentration, protein synthetic rate and (letters), 297
protein kinetics, relationship, amino acid transmembrane transport, dog, 305

Nasogastric tube: *see* Feeding tube
Neonate: *see* Pediatrics
Nitrogen
excretion, acute spinal cord injury, 11
metabolism, excess xylitol effect, TPN-fed rat, 521
Nitrogen balance
during continuous hemodiafiltration, renal failure patient, 379
evaluation, urinary urea excretion and (letter), 191
Nucleotides, modulator of long-chain polyunsaturated fatty acids, weanling rat, 322
Nutrition
anorexia as outcome variable, advanced cancer, 88S
assessment, protein-calorie malnutrition, differentiation of subtypes, 337
clinical trial, health outcome benefits, cancer patients, 106S
molecular cell biology role, 477
preoperative therapy, cancer patients, 100S
Nutrition support
cancer patients, clinical outcome studies, optimal design for, 112S
early posttraumatic, substrate efficacy, 511
efficacy, urinary polyamines as potential marker for, 226
enteral, pulmonary aspiration risk, 160
postoperative, feeding jejunostomy for, current summary, 395
tumor growth stimulation by, 72S, 76S

Oat bran, single cereal breakfast, serum cholesterol lowered by, hyperlipoproteinemic patients, 533
Ornithine α-ketoglutarate, comparison with glutamine, refeeding of food-deprived rats, 505

Parenteral nutrition
  accidental intravenous phosphate intoxication during, postsurgical infants, 558
  aluminum content standards (letters), 92
  bone disease related to, overview, 386, 400 (letter)
  glutamine-supplemented, after bone marrow transplantation, current summary, 589
  home
    advanced malignancies (letter), 190
    cancer patients, 93S
    spontaneous catheter fracture risk, 75
    3-year analysis, 327
  lipid-based, clinical and immunologic effects, AIDS, 165, 496 (letters)
  long-term, cytologic and cholestatic changes, liver (letters), 494
  pediatric solutions, pre- and postfilter copper concentrations, 460
  peripheral
    during pregnancy (letters), 189
    ProcalAmine and lipid combination, 374
  total
    alanyl-glutamine addition, rat, 110
    bone marrow transplant patients (letter), 192
    different lipid sources effect on tumor growth, rat, 545
    endocarditis complication, case reports, 168
    essential amino acids and histidine, complication in patients with renal failure, 581
    essential fatty acid-hepatic steatosis relationship (letters), 399
    excess xylitol effect, rat, 521
    glucose oxidation during, long-chain and medium-chain triglyceride effect, dog, 451
    hepatic steatosis associated with, polymyxin B effect, 529
    inadvertent arterial administration, 284
    leucine/valine-enriched, septic rat, 236
    lipid addition, hepatic steatosis prevention, rat, 106
    lipid-induced hepatic cytolytic and cholestatic changes, 78
    liver function alterations with, 348
    long-term, selenium status determination, 54
    prevention of catheter-related sepsis, new connection device, 581
    priapism associated with, 171
    protein degradation in chronic obstructive pulmonary disease during, 248
    safety evaluation, triple-lumen subclavian catheters, 403
    sebacic acid as fuel substrate, 32
    short-chain fatty acid effect, proximal colon, rat, 1
    stress-induced gastroduodenal lesions and, current summary, 182
    three-in-one solution, stability, infants (letters), 296
    tumor metastases and, current summary, 86
    tumor protein synthesis and, current summary, 290
    vancomycin stability in heparin and TPN solutions, 268
    vitamin E measurement in neonates receiving, 133
Pectin, effect on fat absorption, after small bowel resection, rat, 255
Pediatrics
  Crohn's disease, defined formula diet, intermittent administration, 499
  cuffed polyurethane central venous catheters, 384
  low birth weight infant, vitamin requirements during TPN, 241
  malpostioned central venous catheter, redirection technique, 473
  neonate
    critically ill, concurrent albumin with TPN, 49
    resting energy expenditure, operative stress effect, 333
    vitamin E measurement, patients receiving intravenous lipid emulsions, 133
  parenteral nutrition, accidental phosphate intoxication during, infants, 558
  parenteral nutrition solutions, prefilter and postfilter copper concentrations, 460
  plasma and urinary aluminum levels, term and preterm infants, 157
  three-in-one TPN solutions, stability of (letters), 296
  vitamin E measurement, patients receiving intravenous lipid emulsions, 133
Peptide, -based enteral formula, comparison, standard formula, hypoalbuminemic patients, 20
Peritonitis, experimental, dietary fat composition and, current summary, 87
Phenytoin, interaction, enteral feeding formulations (letters), 95
Phosphate, accidental intravenous intoxication, infants receiving parenteral nutrition, 558
Phospholipids, fatty acid composition, red cell membranes, ICU patients, 136
Polyamines, perioperative excretion, depleted patients with gastrointestinal malignancy, 226
Polymyxin B, TPN-associated hepatic steatosis reduced by, 529
Priapism, TPN-associated, case report, 171
ProcalAmine, lipid emulsion combined with, peripheral parenteral nutrition, 374
Prognostic Inflammatory and Nutritional Index, traumatized patients receiving enteral nutrition support, current summary, 85
Prostaglandin, synthesis, dietary triglyceride effect, mouse peritoneal cells, 316
Protein
  alimentation, during continuous hemodiafiltration, renal failure patient, 379
  degradation, during TPN, chronic obstructive pulmonary disease, 248
  increased catabolism, malnourished cancer patients, 60S
  kinetics, amino acid transmembrane transport and, dog muscle, 305
  malnutrition
    systemic and gut-associated immunity impaired by, mice, 25
    zinc malnutrition and, murine response to infection, 232
  metabolism
    effects of different lipid sources in three TPN solutions, rat, 545
    measurement, cancer patients, 76S
  restriction, role in *Salmonella* outcome, mice, 561
  synthetic rate, muscle glutamine concentration and (letters), 297
Pulmonary disease
  chronic obstructive
    protein degradation during TPN, severely malnourished patients, 248
    resting energy expenditure measurement in patients with, 364

Radiation injury, gut morphology after, intravenous glutamine effect, rat, 440
Renal failure
  continuous hemodiafiltration in patient with, case report, 379
  fat elimination in, long chain vs. medium chain triglycerides, current summary, 590
Residual volume, as marker for enteral feeding intolerance, 99
Respiratory distress, neonatal, concurrent administration, albumin with TPN, 49
Riboflavin, requirement, low birth weight infants during TPN, 241
ROC curve analysis, predictive performance (letter), 594

Salmonella, outcome, role of protein and calorie restriction, mice, 561
Sebacic acid, as fuel substrate, TPN, 32
Seizure, after inadvertent arterial hyperalimentation, 284
Selenium, status, platelet glutathione peroxidase activity and, long-term TPN, 54
Sepsis
  catheter-related
    AIDS patients receiving home parenteral nutrition, 455
    prevention during TPN, new connection device, 581
    single- *vs* triple-lumen, 403
  fatty liver during, prevention by fish oil diet, rat, 353
  leucine/valine-enriched TPN, metabolic effect, rat, 236
  outcome, short-term dietary lipid manipulation effect, mouse, 343
Serotonin, role, pathogenesis of cancer anorexia, 56S
Serum C-reactive protein, role, Prognostic Inflammatory and Nutritional Index, current summary, 85
Short-bowel syndrome
  home parenteral nutrition for, 3-year analysis, 327
  lipid emulsion changes, hepatic cytolytic and cholestatic changes related to, 78
Sip feeds, long-term supplementation, weight-losing cancer patients, 275
Small bowel
  injury, radiation-induced, intravenous glutamine effect, rat, 440
  massive resection, fat absorption after, pectin and cellulose effects, rat, 255
Sodium, role, amino acid transport across cell membrane, 569
Somatostatin, management of gastrointestinal fistula, multicenter trial, current summary, 290

Soy polysaccharide, fiber supplementation by, enteral formula diet, 538
Spectrophotometry, vitamin E measurement, pediatric patients receiving intravenous lipid emulsions, 133
Spinal cord, acute injury, nutritional and metabolic response, 11
Splinting device, effect, measurement of bioelectrical impedance, 408
Stress
  deranged metabolism secondary to, sebacic acid as fuel substrate in TPN, 32
  surgery-associated, effect on resting energy expenditure, neonate, 333
Substrate, efficacy, early nutrition support, multiple trauma victims, 511

T cell, maturation and function, parenteral arginine effect, athymic nude mice, 429
Thermogenesis, nutrient-induced, after intravenous amino acids, rat, 142
Thiamine, requirement, low birth weight infants during TPN, 241
Total nutrition admixture, containing pediatric amino acid formulation, emulsion stability, 64
Trauma-hemorrhagic shock, depressed gut absorptive capacity early after, current summary, 397
Trauma, multiple, early nutrition support, substrate efficacy, 511
Triglyceride
  effect on liver fatty acids and prostaglandin synthesis, mouse peritoneal cells, 316
  medium-chain
    effect on glucose oxidation during TPN, dog, 451
    metabolic clearance, cirrhotic patients, 279
Tryptophan, plasma free, tumor-associated increases, rat, 56S
Tumor
  growth, effects of different lipid sources in three TPN solutions, rat, 545
  metastases, TPN effect, current summary, 86
  protein synthesis, TPN effect, current summary, 291
Tumor necrosis factor-α, role in cancer cachexia, 43S, 50S

Ultrasound, duplex Doppler, role, central venous access for feeding catheters, 264
Underweight patients, glucose and insulin infusion, glucose metabolism and thermogenesis during, 5
Urea, urinary excretion, nitrogen balance evaluation and (letter), 191
Urokinase, infusion, thrombosed central venous catheters, 129, 601 (letters)

Vancomycin, stability, heparin and TPN solutions, catheter-related infection, 268
Vitamin B_{12}, requirement, low birth weight infants during TPN, 241
Vitamin E, measurement, pediatric patients receiving intravenous lipid emulsions, 133

Weight loss, sip feed supplementation, ambulatory cancer patients, 275

Xylitol, excess, effect on nitrogen balance and glucose metabolism, TPN-fed rat, 521

Zinc, malnutrition, protein malnutrition and, murine response to infection, 232

Author Index to Volume 16

Abad-Lacruz A, 359
Abe Y, 142
Adamson M, 49
Aguilaniu B, 248
Alakuijala LA, 226
Alexander HR, 50S
Alexander JW, 232, 343, 561
Alhava E, 226
Allingstrup L, 275
Allison SP, 5
Andrews WL, 241
Arkin CF, 268
Ashley J, 88S
Askanazi J, 165, 248
Astre C, 117

Babayan V, 545
Babcock GF, 561
Barton RG, 122
Bartram P, 43, 533
Bauch TD, 175
Bayle J, 171
Bercovier H, 529
Berg RD, 25
Berkner S, 327
Berry EM, 529
Beverly JL, 56S
Biarent D, 558
Bignami P, 286
Biolo G, 305
Bistrian BR, 76S, 545
Blackburn GL, 112S
Black KW, 39
Blair C, 49
Borg U, 379
Bougle D, 157
Bouton J-M, 558
Bower RH, 106
Boza J, 322
Bozzetti F, 286
Bradford RR, 374
Bray MJ, 369
Briand D, 117
Broadwater JR, 83S
Brown RO, 20
Brumagne C, 558
Bullock L, 64
Bureau F, 157
Burnes JU, 327
Bussy V, 552
Byerley LO, 60S

Cabré E, 359
Calon B, 136
Calvelli T, 165
Cangiano C, 56S
Castagneto M, 32
Cella DF, 106S
Cerra FB, 122
Ceulemans H, 364
Chapman G, 149
Chen K-M, 152
Chen W-J, 152
Chevallier M, 78
Chinkes D, 305
Chlebowski RT, 65S
Ciocon JO, 525
Claudel JP, 78
Clouva-Molyvdas P, 343
Condon SC, 59
Coudray-Lucas C, 505
Cozzaglio L, 286
Curtas S, 149
Cynober L, 505
Czernichow B, 259

Daly JN, 100S
Davidson MI, 69
Dayal R, 106
Day AT, 374
de Boer SY, 16
Deitch EA, 25
Demetriou AA, 289
Devine RM, 327
Diboune M, 136
Doffoel M, 259
Drews D, 521
Duhamel JF, 157
Dusel G, 43

Effertz ME, 538
Ekindijian OG, 505
Elashoff R, 112S
Eloranta TO, 226
Esteve-Comas M, 359

Fan ST, 279
Faus MJ, 322
Ferard G, 136
Fernandez-Bañares F, 359
Finotti E, 32
Fischer JE, 106
Fitzgerald JF, 64
Fleming CR, 301, 327
Frankenfeld D, 379
Frere AM, 171
Freund HR, 529
Friedel D, 1
Friel JK, 241
Fujii M, 178, 581

Galindo-Ciocon DJ, 525
Galindo D, 525
Gallagher H, 100S
Gallen IW, 5
Gallily R, 529
Galluser M, 259
Gassull MA, 359
Gaussorgues P, 78
Gazzaniga AB, 374
Gerard-Boncompain M, 78
Gerlach S, 533
Gil A, 322, 359
Girardot PM, 117
Goldstein-Shapses S, 248
González-Huix F, 359
González J, 359
Gouttebel MC, 117
Greco AV, 32
Greenburg RA, 337
Greene LM, 99
Griffiths DM, 384

Hack S, 133
Haire WD, 129
Halpert C, 88S
Hasebe M, 236
Hasselmann M, 136, 259
Hattner JAT, 499
Haviv Y, 529
Hayashida Y, 142
Heber D, 60S, 88S
Hébuterne X, 171
Henton DH, 133
Herrick L, 327
Herzberg GR, 241
Hill G, 197
Hofstetter G, 43
Hoki M, 54
Howard L, 93S
Hutchins LF, 83S

Imamura I, 110
Ingenbleek Y, 136
Inoue Y, 75, 178, 581
Istfan NW, 76S, 545
Ito-Wong LA, 59

Jansen JBMJ, 16
Jardel A, 505
Jebbink MCW, 16
Jeejeebhoy KN, 219
Jeevanandam M, 511
Jimenez J, 322
Joyeux H, 117

Kamata S, 110
Kanarek KS, 49
Karchmer AW, 268
Kari A, 226
Kasper H, 43, 533
Katz DP, 165
Kearns PJ, 11
Keller F, 533
Kerner JA Jr, 499
Kido Y, 142
Kinsella JE, 316
Kirvelä O, 165
Klimberg VS, 83S
Kobayashi M, 142
Koo WWK, 386
Kudsk KA, 20
Kunio K, 236

Lai H-S, 152
Lamers CBHW, 16
Lampe JW, 538
Lang NP, 83S
Lanza-Jacoby S, 353
Larson JL, 538
Lasnier E, 505
Lazarus T, 165
Leaseburge LA, 348
Le Boucher J, 505
Lee T-S, 579
Leinhardt DJ, 168
Lennard-Jones JE, 264
Leuty JE, 59
Leverve X, 248
Levine GM, 1
Levin R, 112S
Levison RA, 264
Levy P, 248
Levy R, 241
LiCari J, 316
Lieberman RP, 129
Liepold H, 43
Ling PR, 545
Li S, 106
Lloyd DA, 333
Lokech B, 316
Lowen CC, 99
Lowry SF, 43S

Macdonald IA, 5
Maliakkal RJ, 112S
Marechal F, 552
Masclee AAM, 16
Matsuda H, 178, 581
Matsuo Y, 110
Mattox TW, 291
McClave SA, 99, 337
McCombs RJ, 99
McFadden DW, 106
McIntyre AS, 264
McLaughlin AJ, 99
McNamara MJ, 50S
McNamara MP Jr, 284
McSwiggan DA, 369
Meguid MM, 56S, 149
Mendez B, 545
Merritt RJ, 133
Metais P, 136
Mingrone G, 32
Mitoraj TE, 337
Moldawer LL, 43S
Mori E, 236
Mori T, 142
Morotomi Y, 255
Mowatt-Larssen CA, 20
Mughal M, 168
Mullan H, 160
Muscaritoli M, 56S

Nakai S, 75, 178, 581
Namihas BN, 59
Nasca S, 552
Neuville D, 157
Nezu R, 54, 75, 110, 178, 581
Nishio M, 219
Nishi T, 142
Norton JA, 50S
Nussbaum MS, 106
Nwokedi AE, 83S

Ogawa A, 142
O'Hanrahan T, 168
Okada A, 54, 75, 110, 178, 581
O'Keefe SJD, 327
Ovesen L, 275

Pacitti AJ, 569
Page E, 248
Pajon A, 248
Pappas AA, 83S
Pappo I, 529
Payne-James JJ, 369
Pearl W, 175

Peck MD, 232, 343, 561
Periago JL, 359
Peters AW, 69
Petersen S, 511
Pfeifer MA, 99
Phetteplace H, 353
Phillips RKS, 264
Pipp TL, 11
Pitkänen O, 226
Planas R, 359
Polk B, 499
Pöyhönen MJ, 226
Prielipp R, 39

Qi L, 25

Ragavan C, 168
Rampal P, 171
Rana SK, 369
Raul F, 259
Read RC, 83S
Redmond HP, 100S
Reynolds HN, 379
Richter A, 43
Richter F, 43
Robert D, 78
Rodgers L, 99
Rogy MA, 43S
Rossi-Fanelli F, 56S
Roubenoff R, 160
Roubenoff RA, 160
Roy TM, 99
Rubinstein A, 165
Rüthlein J, 43

Saint-Aubert B, 117
Salord F, 78
Sánchez-Medina F, 359
Sando K, 54
Saris WHM, 364
Sarrot F, 248
Sato Y, 255
Sauder P, 136
Sax HC, 589
Sax HS, 290
Scheppach W, 43, 533
Schipper J, 16
Schloerb PR, 348
Schoffelen PFM, 364
Schols AMWJ, 364
Schumer MP, 99
Shamos R, 511
Shanbogue RLK, 333
Shen S-J, 284
Sherman BW, 284
Silk DBA, 369
Singer P, 165
Sirodot M, 78
Slavin JL, 538
Smythe C, 353
Snider HL, 99
Solinger MR, 59
Souba WW, 569
Specian RD, 25
Spielmann D, 136
Stein TP, 521
Stellin GP, 374
Steppe M, 558
Stoughton TL, 175
Strong RM, 59
Sutradhar B, 241

Tabares A, 353
Tacchio RM, 32
Takagi Y, 54, 75, 110, 178, 581
Takala J, 226
Tamada H, 110
Tanaka T, 142
Tayek JA, 65S
Tchekmedyian NS, 60S, 88S
Theilmeier KA, 337
Thompson JD, 11
Tiessen C, 525
Todani T, 255
Toki A, 255
Tominaga GT, 374
Torosian MH, 72S
Tsujinaka T, 142
Tulasne PA, 136

Uemura S, 255

Van Way III CW, 566
Voirin J, 157
Walter WV, 64
Wan JM, 76S
Wasa M, 178, 581
Watanabe Y, 255
Waxman K, 374
Wells CL, 122
Werner PC, 11
Westbrook KC, 83S
Wheeler RA, 384
Willcutts HD, 112S
Willcutts HD Jr, 112S
Williams M, 112S
Williams PR, 49
Wilmot CB, 11
Winn NJ, 348
Wojtysiak SL, 20
Wolfe RR, 305
Wong J, 279
Wood S, 264
Wouters EFM, 364
Wright RA, 99
Wu Y, 579

Xu D, 25

Yang Z-J, 56S
Yao JDC, 268

Zaloga GP, 39
Zhang X-J, 305
Ziegler F, 505

Statement of Ownership, Management and Circulation
(Required by 39 U.S.C. 3685)

1A. Title of Publication	1B. PUBLICATION NO.	2. Date of Filing
Journal of Parenteral and Enteral Nutrition	0 1 4 8 6 0 7 1	
3. Frequency of Issue	3A. No. of Issues Published Annually	3B. Annual Subscription Price
bi-monthly	6	$75 U.S. individual $90 Can/Mex individual ~~$105 Foreign individual~~ $100 U.S. institute ~~$115 Can/Mex institute~~ $130 Foreign institute

4. Complete Mailing Address of Known Office of Publication (Street, City, County, State and ZIP+4 Code) (Not printers)
A.S.P.E.N.
8630 Fenton Street, Suite 412, Silver Spring, MD 20910-3805

5. Complete Mailing Address of the Headquarters or General Business Offices of the Publisher (Not printer)
A.S.P.E.N.
8630 Fenton Street, Suite 412, Silver Spring, MD 20910-3805

6. Full Names and Complete Mailing Address of Publisher, Editor, and Managing Editor (This item MUST NOT be blank)

Publisher (Name and Complete Mailing Address)
A.S.P.E.N.
8630 Fenton Street, Suite 412, Silver Spring, MD 20910-3805

Editor (Name and Complete Mailing Address)
John L. Rombeau, MD, Editor-in-Chief
Dept. of Surgery, Hospital of the Univ. of PA, 3400 Spruce St., Philadelphia, PA 19104

Managing Editor (Name and Complete Mailing Address)
Robin Bodishbaugh, Managing Editor
A.S.P.E.N., 8630 Fenton Street, Suite 412, Silver Spring, MD 20910-3805

7. Owner (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Item must be completed.)

Full Name	Complete Mailing Address
American Society for Parenteral and Enteral Nutrition	8630 Fenton Street, Suite 412 Silver Spring, MD 20910

8. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages or Other Securities (If there are none, so state)

Full Name	Complete Mailing Address
N/A	N/A

9. For Completion by Nonprofit Organizations Authorized To Mail at Special Rates (DMM Section 424.12 only)
The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes: (Check one)
(1) [X] Has Not Changed During Preceding 12 Months (2) [ ] Has Changed During Preceding 12 Months
(If changed, publisher must submit explanation of change with this statement.)

10. Extent and Nature of Circulation (See instructions on reverse side)	Average No. Copies Each Issue During Preceding 12 Months	Actual No. Copies of Single Issue Published Nearest to Filing Date
A. Total No. Copies (Net Press Run)	11,493	10,704
B. Paid and/or Requested Circulation 1. Sales through dealers and carriers, street vendors and counter sales	--	--
2. Mail Subscription (Paid and/or requested)	10,115	9,726
C. Total Paid and/or Requested Circulation (Sum of 10B1 and 10B2)	10,115	9,726
D. Free Distribution by Mail, Carrier or Other Means Samples, Complimentary, and Other Free Copies	402	175
E. Total Distribution (Sum of C and D)	10,517	9,901
F. Copies Not Distributed 1. Office use, left over, unaccounted, spoiled after printing	976	803
2. Return from News Agents	--	--
G. TOTAL (Sum of E, F1 and 2--should equal net press run shown in A)	11,493	10,704

11. I certify that the statements made by me above are correct and complete

Signature and Title of Editor, Publisher, Business Manager, or Owner
Barney Allen, Exec Director

PS Form 3526, January 1991 (See instructions on reverse)